Introduction
The Notch signaling pathway has a crucial role in a variety of cellular functions, including cell proliferation, differentiation, and apoptosis. (1, 2) Notch proteins are heterodimeric transmembrane receptors composed of an extracellular subunit and a transmembrane subunit, and associate with each other via heterodimerization (HD) domains in the extracellular regions. Notch signaling, initiated by receptor-ligand interactions, requires subsequent proteolytic cleavage of the receptor by several proteases, resulting in liberation of the cleaved form of Notch1 that is functionally active (hereafter referred to as aN1) as it translocates into the nucleus and upregulates the transcription of Notch-RBP-Jκ-regulated genes. (3) Recent studies in tumorigenesis of hematologic malignancies and solid tumors revealed several examples of aberrant Notch signaling. (2, 4, 5) Forced expression of aN1 in mouse bone marrow results in the development of T-cell leukemia, (6) and more importantly, amplified Notch signaling contributes to approximately 50% of human T-cell acute lymphoblastic leukemia (T-ALL). (7, 8) The Notch signal amplification in T-ALL is due to gain-of-function mutations in the NOTCH1 gene, which have also been detected in many different murine T-ALL models. (9) (10) (11) (12) NOTCH1 activating mutations cluster at the HD and intracellular domains, leading to ligand-independent cleavage and 6 activation of Notch1, and increased stability of aN1, respectively. Notch1 signaling, whether initiated by receptor-ligand interactions or triggered by NOTCH1-activating mutations in the HD domains, eventually depends on the proteolytic activity of γ-secretase. γ-Secretase inhibitors (GSIs), available as small molecular compounds, suppress Notch signaling by blocking the activity of the γ-secretase complex. (13) Previous studies demonstrated that blockade of Notch signaling with GSI induces cell cycle arrest and apoptosis in a subset of human T-ALL cell lines, (7, 14, 15) and an early-phase clinical trial has already been conducted. (16) Despite that, precise mechanisms of action of GSI on T-ALL in vivo are yet to be elucidated.
Here, to examine the potential clinical applications for GSIs in T-ALL patients, and to evaluate the mechanisms of GSI action, we investigated the effects of the GSI compound YO01027 (17) (referred to hereafter as YO) on human T-ALL growth in murine xenograft models, because YO administration to mice induced defective melanocyte stem cell maintenance but kept the mice otherwise healthy as shown in our previous paper.
The results here indicated that YO is highly effective against T-ALL growth in vivo and demonstrated that the efficacy of GSI might be due to the inhibition of Notch signaling via two mechanisms. 
Materials and Methods
Cell cultures and reagents.
Human T-ALL cell lines (ALL-SIL, DND-41, HPB-ALL, KOPT-K1, TALL-1, MOLT-4, PF-382, and CEM) were obtained from the Fujisaki Cell Center, Hayashibara
Biochemical Laboratories Inc (Okayama, Japan), maintained in RPMI supplemented with 10% fetal bovine serum and penicillin/streptomycin, and incubated at 37°C with 5% CO 2 . Human umbilical vein endothelial cells (HUVEC, Lonza Walkersville Inc.;
Walkersville, USA) were cultured in Endothelial Basal Medium-2 and SingleQuots (Lonza Walkersville Inc.). The YO, which is an LY-411,575 analogue, was synthesized as described previously. (17) YO was dissolved in dimethyl sulfoxide (DMSO) to create 10 mM or 50 mM stock solutions.
Animals.
SCID mice (C.B-17/Icr-scid/scidJcl; 6 weeks old, female) were purchased from CLEA Japan, Inc. (Tokyo, Japan) and maintained under specific pathogen-free conditions.
All experimental procedures were performed in accordance with the guidelines for animal experiments of the University of Tokyo and Jichi Medical University.
Xenograft mouse model.
SCID mice at 6 to 8 weeks of age were inoculated subcutaneously in the right flank 8 with 3 × 10 7 cells in 300 μl of phosphate buffered saline (PBS). In concurrent administration experiments, the mice were assigned to a control group and a YO-treated group the day after tumor inoculation. YO was orally administered daily for at least 30 days at a dose of 0.1 or 1 mg/kg/day. In challenge experiments for established tumors, mice were similarly assigned as described above at approximately 2.5 to 3
weeks (in HPB-ALL and TALL-1) or 8 to 12 weeks (in ALL-SIL and DND-41) after tumor cell inoculation, when tumor size had reached a certain volume. YO was orally administered daily at a dose of 0.1, 1, or 10 mg/kg/day. Tumor size was measured at the greatest length and width. The volume was calculated as 1/2 × (tumor length) × (tumor width) 2 .
In vivo administration of YO.
In vivo administration of YO was performed as described previously. (19) Briefly, 0.1 to 10 mg/kg of YO or an equal volume of vehicle (DMSO) in 300 μl of 0.5% methylcellulose (Wako; Osaka, Japan) was administered orally to SCID mice using a disposable oral zonde (FUCHIGAMI; Kyoto, Japan) once a day for the indicated periods.
Plasmid construction and retroviral transduction.
The cDNA for myc-tagged murine aN1 (20) was subcloned into the BamHI restriction site 
Retroviral transduction of a human T-ALL cell line, DND-41, was performed using PLAT-F cells as described previously. (21) Following transduction, GFP-positive cells were sorted to 90% purity and used for further analysis. The proteins were detected by Western blotting using an anti-myc antibody (9E10).
Proliferation assay.
Cell growth was quantified using a WST-1-based assay (Cell Counting Kit-8, Dojindo
Medical Technologies; Kumamoto, Japan), which is a highly sensitive colorimetric 
Detection of apoptosis.
Cells were incubated with various concentrations of YO for the indicated periods.
Apoptosis was assessed using a fluorescein isothiocyanate (FITC)-labeled Annexin V staining kit (Immunotech, Beckman-Coulter; Praha, Czech Republic) combined with 7-amino-actinomycin D (7-AAD), according to the manufacturer's instructions, with a FACS Calibur cytometer (BD Biosciences; San Jose, USA).
TUNEL staining
To detect apoptotic cells, ALL-SIL-bearing SCID mice were sacrificed after the treatment with 1 mg/kg YO or vehicle for 5 days. Frozen blocks of tumors were cryosectioned and fixed with 1% paraformaldehyde, followed by analysis for apoptosis using ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit (MILLIPORE; Billerica, USA) according to the manufacturer's instructions.
Western blotting.
Western blotting was performed as described previously. (22) The probes used were antibodies against cleaved Notch1 (Val1744) (Cell Signaling Technology; Danvers, USA) and GAPDH as a control. The Val1744 antibody was incubated at a dilution of 1:1000 overnight.
Tube formation assay
Upon the BD BioCoat Angiogenesis Plate (96 well; BD Biosciences; San Jose, USA), 2
x 10 4 HUVEC were seeded per each well, with or without 100 nM YO. After 18 h, 11 cells were stained with fluorescent dye, Calcein AM (BD Biosciences; San Jose, USA), according to the manufacturer's instructions. Images were captured with the microscope BIOREVO BZ-9000 (KEYENCE; Osaka, Japan), and the tube length was measured using BZ-H1C image analysis application (KEYENCE; Osaka, Japan).
Histological analysis.
Frozen blocks were cryosectioned at 5 μm and mounted on the slides. Histological sections were air-dried and fixed in acetone for 
Statistics.
Statistical analyses were performed using Student's t test. A p value of less than 0.05 was considered statistically significant.
Results

Human T-ALL lines are susceptible to Notch inhibition.
Some human T-ALL cell lines with NOTCH1 activating mutations are sensitive to GSI in vitro. (7, (13) (14) (15) We examined the ability of YO, a GSI compound that has not Next, we explored whether the decreased proliferation of T-ALL cell lines after treatment with YO was due to the induction of cell cycle arrest and/or apoptosis. We analyzed the cell cycle of the T-ALL cell lines after YO treatment using flow cytometry.
As expected from previous reports, (7, (13) (14) (15) YO induced G0-G1 arrest in all the T-ALL cell lines sensitive to YO (data not shown). Then, we treated five T-ALL cell lines with YO for 7 days followed by Annexin V/7-AAD staining, and found that YO induced significant apoptosis of DND-41 cells (Fig. 1D) , as well as the other T-ALL cell lines tested (Fig. 1E) . Similar results were observed using a pharmacologically distinct GSI, DAPT, known to block Notch activation (data not shown). Taken together, these results confirmed that some human T-ALL cell lines are susceptible to YO treatment in vitro.
Concurrent administration of YO with tumor inoculation resulted in the inhibition of tumor growth in T-ALL xenograft models.
To examine in vivo antitumor effects of YO, we used murine xenograft models, in which SCID mice were inoculated subcutaneously with human cell lines.
HPB-ALL and TALL-1 cell lines establish subcutaneous tumors in 2.5 to 3 weeks after the inoculation. The subcutaneous tumors of the YO-treated groups were significantly 14 smaller than those of control groups 2.5 to 4 weeks after the inoculation and the initiation of concurrent administration of YO or vehicle. Notably, in mice treated with 1 mg/kg of YO, there was no tumor formation observed in any of the TALL-1-inoculated mice or in approximately half the HPB-ALL-inoculated mice ( Fig. 2A,B) . This result indicates that YO exerts in vivo antitumor effects on T-ALL, at least during the period of tumor engraftment.
YO treatment against established tumors in T-ALL xenograft models results in partial or complete regression.
Next, we evaluated the effects of YO treatment when the tumors grew to visible sizes. In this experimental design, YO treatment resulted in partial (HPB-ALL) or complete (ALL-SIL, DND-41, and TALL-1) regression of the established subcutaneous tumors. When treated with 10 mg/kg/day YO, the growth of tumors derived from HPB-ALL was suppressed to less than 50% compared with growth without treatment. Tumors derived from ALL-SIL, DND-41, and TALL-1 completely regressed within 2 to 3 weeks following treatment with YO at 1 mg/kg/day (Fig. 3A) .
To confirm the in vivo pharmacologic inhibition of Notch signaling by YO, we excised tumors made of ALL-SIL from mice with or without 1 or 10 mg/kg/day YO treatment for 3 days, followed by immunoblotting of the tumor lysates with the Val1744
antibody. The level of cleaved Notch1 was reduced partially or almost completely after 1 or 10 mg/kg/day YO treatment, respectively. Thus, YO administered at both 1 and 10 mg/kg/day to SCID mice was pharmacologically active, and blocked Notch1 signaling partially or almost completely, at least in cells of subcutaneous tumors (Fig.   3B ).
To determine whether YO treatment induces apoptosis in vivo, we performed TUNEL staining on tumors made of ALL-SIL, which was isolated from vehicle-or YO-treated mice. TUNEL-positive cells were reproducibly increased in number by the YO treatment (Fig. 3C) , demonstrating increased apoptosis of T-ALL cells in vivo.
Effect of aN1 expression in tumor growth during YO treatment.
We next expressed aN1 exogenously in DND-41 cell lines to examine whether aN1 rescues YO-induced cell growth arrest and tumor regression. aN1 represents a protein that is already cleaved, and is thus not a substrate for γ-secretase. Therefore, it is expected that DND-41 cells transduced with aN1 (hereafter referred to as DND-41/aN1) would become resistant to YO treatment.
We established DND-41/aN1 cells by infection of parental DNA-41 cells with aN1-expressing retrovirus, followed by bulk sorting of GFP-positive cells. Expression of aN1 proteins was confirmed by Western blotting with an anti-myc antibody (Fig. 4A) .
Parental DND-41 and mock-infected DND-41 (DND-41/mock) were sensitive to YO, but, as expected, DND-41/aN1 was substantially resistant to YO in vitro when assessed by a cell proliferation assay (Fig. 4B) (Fig. 4C,D) . Interestingly, in vivo YO treatment of tumors derived from DND-41/aN1 and DND-41/aN1/GSI cells, which were resistant to YO in vitro, induced significantly slower cell growth compared with the vehicle treatment, suggesting that 17 these cells were sensitive to YO to some degree in vivo (Fig. 4C,D) . In some mice, we observed a stabilization of the tumor volume. Nevertheless, YO treatment was not sufficiently effective on DND-41/aN1 and DND-41/aN1/GSI to regress the tumors to an unpalpable level, unlike parental DND-41-and DND-41/mock-derived tumors.
Effect of YO on in vitro tube formation and in vivo tumor vessels.
Recent studies have demonstrated that inhibition of Notch signaling in solid tumors resulted in tumor regression via increased tumor vessels with poor perfusion. (23) (24) (25) (26) It has been shown that Notch inhibition leads to promotion of non-functioning angiogenesis.
Tube formation assay was performed to investigate the effect of YO on in vitro angiogenesis using HUVEC. We found that YO treatment significantly increased the tube length in the tube formation assay (Fig. 5A,B) , suggesting that Notch inhibition promoted proliferation of endothelial cells, which is consistent with previous studies. (24, 27) In addition, cell proliferation in the presence of VEGF was measured with WST-1-based assay. YO significantly promoted proliferation of HUVEC (Fig.   5C ) as previously reported. (24, 27) To further clarify the mechanism of action with YO treatment, we analyzed the 
Discussion
The findings of the present study confirmed that the YO compound that we synthesized is a GSI that efficiently blocks Notch signaling in T-ALL cell lines carrying activating NOTCH1 mutations and induces apoptosis of these cell lines in vitro. The cell-autonomous effect against Notch signaling described here is postulated to be the mechanism of anti-T-ALL, creating the bases for clinical studies of a GSI targeting
We demonstrated a marked in vivo effect of YO in a xenograft model that was more dramatic than we had expected. Although the mechanisms of YO action on T-ALL have been virtually confined to the cell-autonomous Notch signal inhibition, including a recent report describing the combinatorial effect of steroid with GSI, (28) the strong effect of GSI in vivo could also be attributed to cell-non-autonomous inhibition of Notch signaling.
Our findings were consistent with the recent reports on the role of Notch signaling in tumor angiogenesis. We confirmed that subcutaneous tumors made of a colon cancer cell line, LoVo, which was non-sensitive to YO in vitro, were partially regressed by YO at 10 mg/kg/day (data not shown). The effect of YO on the LoVo tumors, however, was not as strong as on tumors made of parental DND-41 and several other T-ALL cell lines, again supporting the idea that the exceptionally strong effect of YO on T-ALL xenografts is due to the inhibiting effect of YO on Notch signaling at two independent targets in vivo.
As shown in weeks did not cause weight loss, diarrhea, or hair coat abnormalities in mice, treatment at 10 mg/kg/day for more than 2 weeks resulted in obvious weight loss, diarrhea, and hair coat roughness. This implies a narrow window of YO for the treatment purpose.
Nevertheless, it also indicates that the sensitivity to YO is variable among tissues and cells, and this difference might be important for YO to be considered as a drug.
Together with the results described in previous papers, (18, 29, 30) a subset of T-ALL cells in tumors derived from DND-41. * P<0.05, statistically significant differences.
